Arab Pharmaceuticals

Arab Pharmaceuticals

EEGX:ADCI
264.50
EGP
+2.00
(+0.76%)
Arab Pharmaceuticals
EGX:ADCI
(Egyptian Exchange)

Recent

price

264.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Arab Pharmaceuticals (The Arab Drug Company - ADCO, EGX:ADCI) is an Egypt-based public shareholding company that specializes in the research, development, manufacturing, marketing, and distribution of human pharmaceuticals, medicinal supplies, cosmetics, and veterinary healthcare products. Founded in 1963 and headquartered in Cairo, Egypt, the company operates as a key subsidiary of the state-owned Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies (HoldiPharma). Arab Pharmaceuticals produces a diversified portfolio encompassing over 130 formulations across 40 therapeutic categories, including cardiovascular agents; central nervous system (CNS) medications; anti-infectives and antibiotics; respiratory treatments; gastrointestinal drugs; analgesics, antipyretics, and anti-inflammatory compounds; dermatological preparations; metabolic and endocrine therapies; dietary supplements and multivitamins; and animal health formulations. The company’s manufacturing operations encompass multiple finished dosage forms, comprising specialized pressurized metered-dose inhalers and topical aerosols, where it operates as a regional market leader; solid oral formulations including film-coated, uncoated, and extended-release tablets as well as hard gelatin capsules; liquid oral dosages including syrups, suspensions, solutions, and oral drops; sterile parenteral preparations including injectable ampoules; and topical semisolids including therapeutic creams, ointments, and gels. In addition to commercial manufacturing, Arab Pharmaceuticals provides contract toll manufacturing, formulation development, quality control testing, and packaging services for third-party pharmaceutical entities. The company distributes its products domestically across Egyptian hospital, retail pharmacy, and public tender channels, while exporting to approximately 40 markets across the Middle East, Africa, and Asia. In recent developments, Arab Pharmaceuticals has advanced extensive modernization and capital expenditure programs across its Cairo production facilities to align with updated Good Manufacturing Practice (GMP) guidelines under the supervision of the Egyptian Drug Authority (EDA); expanded automated filling and packaging capacity for syrups, suspensions, and oral drop production lines; broadened its commercial portfolio through the registration of new nutritional supplements and the relaunch of strategic legacy formulations; implemented enterprise resource planning (ERP) infrastructure upgrades under HoldiPharma’s digital transformation initiative; and increased its authorized and issued share capital base to support sustained manufacturing expansion and export growth.